We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NanoViricides - Nanobiotechnology
NNVC 4.000-1.0%Sep 22 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: donpat3/5/2019 8:33:16 AM
of 1214
NanoViricides announces $2.5M financing in registered direct offering


FEBRUARY 27, 2019

NanoViricides Inc., a Shelton-based company that is developing nanotechnology based antiviral medicines, announced Wednesday it is entering into a securities purchase agreement with institutional investors.

The agreement provides for the purchase and sale of over 6.9 million units at a price of $0.36 per unit, according to a press release. Each unit represents one share of common stock and one five-year warrant exercisable at $0.61.

The company is developing medication aimed at viral diseases such as influenza, swine flu, bird flu, HIV/AIDS, cold sores and genital herpes, viral eye diseases, dengue viruses, Ebola virus, rabies, and more.

In early February, the company announced it had selected a clinical candidate for further development under the HerpeCide broad-spectrum drug program, a topical skin cream expected to be effective for treating the shingles rash. Shingles in adults is caused by the same virus as the chicken pox in children, and there currently is no effective treatment for it.

"The market size for an effective anti-shingles drug is currently estimated to be in the range of billions of dollars, even after a new shingles vaccine, Shingrix (GlaxoSmithKline) has been approved," the company said in a press release.

According to company officials, their drug candidates against cold sores and genital herpes are in advanced studies and are expected to follow the shingles drug candidate into human clinical trials.

The investment bank Chardan acted as the placement agent in connection with the financing, according to NanoViricides, which expected the closing of the sale of the securities to take place on Wednesday.

NanoViricides officials believe this financing will provide key capital to immediately help it advance its drugs into human clinical trials.

The company will file a prospectus supplement related to the shares of common stock with the U.S. Securities and Exchange Commission, which will be available at
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext